Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, meow meow) in the United Kingdom

Journal of Clinical Psychopharmacology

Volumn 32, Issue 5, 2012, Pages 710-714

  Schifano, Fabrizio ^a,b,c   Corkery, John ^a,c   Ghodse, A Hamid ^c  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b HERTFORDSHIRE PARTNERSHIP UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

cathinones; drug misuse; drug related deaths; meow meow; mephedrone; np SAD

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4' METHYLMETHCATHINONE; AMPHETAMINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATROPINE; BUPRENORPHINE; CANNABIS; COCAINE; CODEINE; DIAZEPAM; DIHYDROCODEINE; HOMOCOCAINE; KETAMINE; LEVAMISOLE; LIDOCAINE; LORAZEPAM; METHADONE; METHAMPHETAMINE; METHYLONE; MORPHINE; NEUROLEPTIC AGENT; NITRAZEPAM; OXYCODONE; PAPAVERINE; PIPERAZINE DERIVATIVE; SCOPOLAMINE; ZOPICLONE;

ADULT; ARTICLE; DEATH; DESCRIPTIVE RESEARCH; DRUG DEPENDENCE; DRUG MISUSE; FEMALE; HANGING; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SUBSTANCE ABUSE; UNITED KINGDOM;

ADOLESCENT; ADULT; DATABASES, FACTUAL; FEMALE; GREAT BRITAIN; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; SELF-INJURIOUS BEHAVIOR; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84865860920     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318266c70c     Document Type: Article

References (34)

1. Campbell D. Online sales of legal alternatives to class A drugs raise safety fears. Available at: http://www.guardian.co.uk/society/2009/mar/12/ online-legal-drugs-stimulants, 2009. Accessed August 19, 2010.
2. Gustaffsson D, Escher C. Mefedron. Internetdrog som tycks ha kommit fö r att stanna (Mephedrone-Internet drug that seems to have come to stay). Läkartidningen. 2009;106:2769-2771.
3. Dickson AJ, Vorce SP, Levine B, et al. Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J Anal Toxicol. 2010;34:162-168.
4. Lusthof KJ, Oosting R, Maes A, et al. A case of extreme agitation and death after the use of mephedrone in the Netherlands. Forensic Sci Int. 2011;206:e93Ye95.
5. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the Risk Assessment of Mephedrone in the Framework of the Council Decision on New Psychoactive Substances. Luxembourg: Publications Office of the European Union; 2011.
6. Schifano F, Albanese A, Fergus S, et al. Mephedrone (4- methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacol (Berl). 2011;214:593-602.
7. Advisory Council on the Misuse of Drugs/ACMD (2010) Consideration of the Cathinones. Available at: http://www.homeoffice.gov.uk/publications/drugs/acmd1/ acmd-cathinodes-report-2010. Accessed August 18, 2010.
8. Morris K. UK places generic ban on mephedrone drug family. Lancet. 2010;9723:1333-1334.
9. Deluca P, Schifano F, Davey Z, et al. Mephedrone Report. Institute of Psychiatry, King's College London, London (UK), 2009. Available at: www.psychonautproject.eu. Accessed August 19, 2010.
10. Winstock AR, Marsden J, Mitcheson L. What should be done about mephedrone? BMJ. 2010;340:c1605.
11. Dargan PI, Albert S,Wood DM. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM. 2010;103:875-879.
12. Winstock A, Mitcheson L, Deluca P, et al. Mephedrone; new kid for the chop. Addiction. 2011;106:154-161.
13. Feyissa AM, Kelly JP. A review of the neuropharmacological properties of khat. Progr Neuropsychopharmacol Biol Psychiatry. 2008;32: 1147-1166.
14. Kalix P. Pharmacological properties of the stimulant khat. Pharmacol Ther. 1990;48:397-416.
15. Wood DM, Davies S, Puchnarewicz M, et al. Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol. 2010;6(3):327-330.
16. EuropolYEMCDDA. Joint report on a new psychoactive substance: 4-methylmethcathinone (mephedrone). Available at: http://www.emcdda. europa.eu/attachements.cfm/att-102496-EN-Europol-EMCDDA-Joint-Report-Mephedrone. pdf. Accessed August 16, 2010.
17. James D, Adams RD, Spears R, et al, National Poisons Information Service. Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg Med J. 2011;28(8):686-689.
18. Wood DM, Davies S, Puchnarewicz M, et al. Recreational use of 4-methylmethcathinone (4-MMC) presenting with sympathomimetic toxicity and confirmed by toxicological screening. Clin Toxicol. 2009;47:7331.
19. Wood DM, Greene SL, Dargan PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J. 2011;28(4):280-282.
20. Ghodse AH, Corkery J, Oyefeso A, et al. Drug Related Deaths in the UK. Annual Report 2010. London, UK: International Centre for Drug Policy, St George's University of London (UK); 2010.
21. Torrance H, Cooper G. The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci Int. 2010;202:e62Ye63.
22. Maskell PD, De Paoli G, Seneviratne C, et al. Mephedrone (4-methylmethcathinone)Yrelated deaths. J Anal Toxicol. 2011;35: 188-191.
23. Mackay K, Taylor M, Bajaj N. The adverse consequences of mephedrone use: a case series. Psychiatrist. 2011;35:203-205.
24. Davey Z, Corazza O, Schifano F, et al. Mass-information: mephedrone, myths, and the new generation of legal highs. Drugs Alcohol Today. 2010;10:24-28.
25. Smith K, Flatley J, eds. DrugMisuse Declared: Findings From the 2010/11 British Crime Survey England and Wales. 2011. Home Office Statistical Bulletin 12/11. Home Office Research, Development and Statistics Directorate, London. Available at: http://www.homeoffice.gov.uk/publications/science-research- statistics/research-statistics/crime-research/hosb1211/hosb1211?view=Binary. Accessed July 28, 2011.
26. Pacifici R, Zuccaro P, Farre M, et al. Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings. Ann N Y Acad Sci. 2002;965:421-433.
27. Schifano F, Oyefeso A, Corkery J, et al. Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002. Hum Psychopharmacol Clin Exp. 2003;18:519-524.
28. Schifano F, Corkery J, Naidoo V, et al. Comparison between amphetamine/methylamphetamine and ecstasy (MDMA, MDEA,MDA, 4-MTA) mortality data in the UK (1997-2007). Neuropsychobiology. 2010;61:122-130.
29. Schifano F, Oyefeso A,Webb L, et al. Review of deaths related to taking ecstasy, England and Wales, 1997-2000. BMJ. 2003;326:80-81.
30. Schifano F, Corkery J. Cocaine/crack cocaine consumption, treatment demand, seizures, related offences, prices, average purity levels and deaths in the UK (1990-2004). J Psychopharmacol. 2008;22:71-79.
31. Corkery JM, Schifano F, Oyefeso A, et al. 'Bundle of fun' or 'bunch of problems'? Case series of khat-related deaths in the UK. Drugs Educ Prev Policy. 2011;18(6):408-425.
32. Smith K, Flatley J. Drug Misuse Declared: Findings from the 2010/11 British Crime Survey England and Wales. Available at: http://www.homeoffice.gov. uk/publications/science-research-statistics/research-statistics/crime-research/ hosb1211/. Accessed August 4, 2011.
33. Benzie F, Hekman K, Cameron L, et al. Emergency department visits after use of a drug sold as "bath salts"VMichigan, November 13, 2010YMarch 31, 2011. MMWR Morb Mortal Wkly Rep. 2011;60: 624-627.
34. Hadlock GC, Webb KM, McFadden LM, et al. 4- Methylmethcathinone(mephedrone): neuropharmacological effects of a designer stimulant of abuse [published online ahead of print August 2, 2011]. J Pharmacol Exp Ther.